# Pulmonary vasodilator therapy is associated with improved survival in COPD-PH with pulmonary vascular predominance

## TL;DR

Pulmonary vasodilator therapy improves survival in COPD patients with severe pulmonary hypertension and a vascular component.

## Contribution

Identifies a subgroup of COPD-PH patients who benefit from pulmonary vasodilator therapy based on vascular markers.

## Key findings

- Pulmonary vasodilator therapy reduced the risk of death or transplant in COPD-PH patients with PVR > 5 WU.
- Patients with both PVR > 5 WU and mPAP > 40 mmHg had the strongest survival benefit from the therapy.
- The benefit persisted after adjusting for disease severity and COPD treatment.

## Abstract

Pulmonary hypertension (PH) is a prevalent comorbidity associated with COPD accountable for increased mortality, exacerbation frequency, and progressive clinical course. Studies examining pulmonary vasodilator therapy in COPD-PH have shown mixed results, likely due to the heterogenous nature of PH in COPD. We aimed to assess whether pulmonary vasodilator therapy is associated with improvement in transplant-free survival in patients with COPD and severe PH. A retrospective study of patients with COPD and PH defined as a mean pulmonary artery pressure (mPAP) greater than 20 mmHg was conducted. Right heart catheterization data, pulmonary function testing, pulmonary vasodilator therapy, and outcome data including death and transplant were collected. Transplant-free survival analysis was performed via Kaplan-Meier and multivariable cox regression. PH therapy was significantly and independently associated with reduced risk of death or transplant in patients with PVR > 5 WU (HR 0.29, 95% CI 0.10–0.81, p = 0.02) and patients with PVR > 5 WU and mPAP > 40 mmHg (HR 0.11, 95% CI, 0.17–0.74, p = 0.02), even when accounting for other markers of disease severity (GOLD stage, DLCO, 6MWD, O2 requirement, BNP) and COPD treatment (triple inhaled therapy). Pulmonary vasodilator therapy had the most significant association with reduced risk of death or transplant among those with both PVR > 5 WU and mPAP > 40 mmHg, suggesting that patients with a significant pulmonary vascular phenotype may benefit from these therapies.

The online version contains supplementary material available at 10.1186/s12890-026-04203-4.